Rilimogene Galvacirepvec/Rilimogene Glafolivec clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How each study uses Rilimogene Galvacirepvec/Rilimogene Glafolivec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- PROSTVAC-V/F
- 2
Studies by the year they started
4 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2016 | 2 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
National Cancer Institute (NCI) (1) · Bavarian Nordic (1) · Medical University of South Carolina (1) · Lawrence Fong (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Rilimogene Galvacirepvec/Rilimogene Glafolivec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical ProstatectomyTerminatedPhase 2Medical University of South CarolinaNCT02772562Written as PROSTVAC-V/FHow we know
- PROSTVAC in Combination With Nivolumab in Men With Prostate CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT02933255Written as PROSTVAC-V/FHow we know
- Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate CancerTerminatedPhase 2Lawrence FongNCT02506114Written as PROSTVAC V/FHow we know
- PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone TherapyCompletedPhase 2Bavarian NordicNCT00078585Written as PROSTVAC®-VF/TRICOM™How we know